Abstract
The complete herpes simplex virus type 2 envelope glycoprotein G was represented by overlapping synthetic peptides. Herpes simplex virus type 2-specific human seroreactivities were mainly seen against three peptides, peptides G2-64, G2-69, and G2-70, located in the C-terminal part of glycoprotein G. This is, interestingly, a region which has strong homology between herpes simplex virus types 1 and 2. G2-69 was the most herpes simplex virus type 2-specific peptide, reacting with 93% (13 of 14) of herpes simplex virus type 2 immunoglobulin G-positive human serum samples (n = 14) and none of the type 2 negative serum samples (n = 16) tested. The epitope of peptide G2-69 was mapped to the amino acid sequence RYAHPS, and the antibody binding to G2-64 could be increased by chemical oxidation of the peptide. The three reactive peptides were used, alone or combined, together with herpes simplex virus type 2 antigen in an attempt to discriminate anti-herpes simplex virus type 2 from anti-herpes simplex virus type 1 immunoglobulin G. Inclusion of the herpes simplex virus type 2 glycoprotein G peptides increased the specificity compared with the use of glycoprotein G alone. Combinations of peptides with whole glycoprotein also showed a greater discriminative capacity than single peptides. We conclude that these synthetic glycoprotein G peptides may be useful for herpes simplex virus type 2 serology based on peptides or combinations of peptides and antigens. This is the first study describing the possibility of discriminative herpes simplex virus serology by using synthetic peptides combined with small amounts of whole glycoprotein G.
Full Text
The Full Text of this article is available as a PDF (210.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ashley R. L., Militoni J., Lee F., Nahmias A., Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988 Apr;26(4):662–667. doi: 10.1128/jcm.26.4.662-667.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother. 1993 Jul;32 (Suppl A):121–132. doi: 10.1093/jac/32.suppl_a.121. [DOI] [PubMed] [Google Scholar]
- Field P. R., Ho D. W., Irving W. L., Isaacs D., Cunningham A. L. The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology. 1993 Apr;25(2):175–179. doi: 10.3109/00313029309084794. [DOI] [PubMed] [Google Scholar]
- Ho D. W., Field P. R., Irving W. L., Packham D. R., Cunningham A. L. Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol. 1993 Dec;31(12):3157–3164. doi: 10.1128/jcm.31.12.3157-3164.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ho D. W., Field P. R., Sjögren-Jansson E., Jeansson S., Cunningham A. L. Indirect ELISA for the detection of HSV-2 specific IgG and IgM antibodies with glycoprotein G (gG-2). J Virol Methods. 1992 Mar;36(3):249–264. doi: 10.1016/0166-0934(92)90056-j. [DOI] [PubMed] [Google Scholar]
- McGeoch D. J., Moss H. W., McNab D., Frame M. C. DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons. J Gen Virol. 1987 Jan;68(Pt 1):19–38. doi: 10.1099/0022-1317-68-1-19. [DOI] [PubMed] [Google Scholar]
- Muñoz N., Kato I., Bosch F. X., De Sanjosé S., Sundquist V. A., Izarzugaza I., Gonzalez L. C., Tafur L., Gili M., Viladiu P. Cervical cancer and herpes simplex virus type 2: case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. Int J Cancer. 1995 Feb 8;60(4):438–442. doi: 10.1002/ijc.2910600403. [DOI] [PubMed] [Google Scholar]
- Olofsson S., Jeansson S., Lycke E. Unusual lectin-binding properties of a herpes simplex virus type 1-specific glycoprotein. J Virol. 1981 May;38(2):564–570. doi: 10.1128/jvi.38.2.564-570.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olofsson S., Lundström M., Marsden H., Jeansson S., Vahlne A. Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92K or gG. J Gen Virol. 1986 Apr;67(Pt 4):737–744. doi: 10.1099/0022-1317-67-4-737. [DOI] [PubMed] [Google Scholar]
- Parkes D. L., Smith C. M., Rose J. M., Brandis J., Coates S. R. Seroreactive recombinant herpes simplex virus type 2-specific glycoprotein G. J Clin Microbiol. 1991 Apr;29(4):778–781. doi: 10.1128/jcm.29.4.778-781.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Straus S. E., Corey L., Burke R. L., Savarese B., Barnum G., Krause P. R., Kost R. G., Meier J. L., Sekulovich R., Adair S. F. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994 Jun 11;343(8911):1460–1463. doi: 10.1016/s0140-6736(94)92581-x. [DOI] [PubMed] [Google Scholar]
- Straus S. E., Savarese B., Tigges M., Freifeld A. G., Krause P. R., Margolis D. M., Meier J. L., Paar D. P., Adair S. F., Dina D. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis. 1993 May;167(5):1045–1052. doi: 10.1093/infdis/167.5.1045. [DOI] [PubMed] [Google Scholar]
- Sánchez-Martínez D., Pellett P. E. Expression of HSV-1 and HSV-2 glycoprotein G in insect cells by using a novel baculovirus expression vector. Virology. 1991 May;182(1):229–238. doi: 10.1016/0042-6822(91)90666-y. [DOI] [PubMed] [Google Scholar]